Literature DB >> 16819549

E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis.

Cho-Rok Jung1, Kyung-Sun Hwang, Jinsang Yoo, Won-Kyung Cho, Jin-Man Kim, Woo Ho Kim, Dong-Soo Im.   

Abstract

The von Hippel-Lindau tumor suppressor, pVHL, forms part of an E3 ubiquitin ligase complex that targets specific substrates for degradation, including hypoxia-inducible factor-1alpha (HIF-1alpha), which is involved in tumor progression and angiogenesis. It remains unclear, however, how pVHL is destabilized. Here we show that E2-EPF ubiquitin carrier protein (UCP) associates with and targets pVHL for ubiquitin-mediated proteolysis in cells, thereby stabilizing HIF-1alpha. UCP is detected coincidently with HIF-1alpha in human primary liver, colon and breast tumors, and metastatic cholangiocarcinoma and colon cancer cells. UCP level correlates inversely with pVHL level in most tumor cell lines. In vitro and in vivo, forced expression of UCP boosts tumor-cell proliferation, invasion and metastasis through effects on the pVHL-HIF pathway. Our results suggest that UCP helps stabilize HIF-1alpha and may be a new molecular target for therapeutic intervention in human cancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16819549     DOI: 10.1038/nm1440

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  53 in total

Review 1.  Substrate-specific regulation of ubiquitination by the anaphase-promoting complex.

Authors:  Ling Song; Michael Rape
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

2.  Control of APC/C-dependent ubiquitin chain elongation by reversible phosphorylation.

Authors:  Allison Craney; Aileen Kelly; Luying Jia; Indro Fedrigo; Hongtao Yu; Michael Rape
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-25       Impact factor: 11.205

3.  Deregulation of E2-EPF ubiquitin carrier protein in papillary renal cell carcinoma.

Authors:  Frederik C Roos; Andrew J Evans; Walburgis Brenner; Bill Wondergem; Jeffery Klomp; Pardeep Heir; Olga Roche; Christian Thomas; Heiko Schimmel; Kyle A Furge; Bin T Teh; Joachim W Thüroff; Christian Hampel; Michael Ohh
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 4.  State of the APC/C: organization, function, and structure.

Authors:  Janel R McLean; Denis Chaix; Melanie D Ohi; Kathleen L Gould
Journal:  Crit Rev Biochem Mol Biol       Date:  2011-01-24       Impact factor: 8.250

5.  Adenovirus-mediated E2-EPF UCP gene transfer prevents autoamputation in a mouse model of hindlimb ischemia.

Authors:  Jung Hwa Lim; Hyo Jung Shin; Kyeong-Su Park; Chan Hee Lee; Cho-Rok Jung; Dong-Soo Im
Journal:  Mol Ther       Date:  2012-01-31       Impact factor: 11.454

6.  The ubiquitin-conjugating enzyme E2-EPF is overexpressed in primary breast cancer and modulates sensitivity to topoisomerase II inhibition.

Authors:  Donato Tedesco; Jianhuan Zhang; Lan Trinh; Guita Lalehzadeh; Rene Meisner; Ken D Yamaguchi; Daniel L Ruderman; Harald Dinter; Deborah A Zajchowski
Journal:  Neoplasia       Date:  2007-07       Impact factor: 5.715

7.  Proteome-wide Analysis Reveals Substrates of E3 Ligase RNF146 Targeted for Degradation.

Authors:  Litong Nie; Chao Wang; Nan Li; Xu Feng; Namsoo Lee; Dan Su; Mengfan Tang; Fan Yao; Junjie Chen
Journal:  Mol Cell Proteomics       Date:  2020-09-21       Impact factor: 5.911

8.  Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor.

Authors:  W Liu; H Xin; D T Eckert; J A Brown; J R Gnarra
Journal:  Oncogene       Date:  2010-08-30       Impact factor: 9.867

9.  The predictive role of E2-EPF ubiquitin carrier protein in esophageal squamous cell carcinoma.

Authors:  Miao-Fen Chen; Kuan-Der Lee; Ming-Shian Lu; Chih-Cheng Chen; Ming-Ju Hsieh; Yun-Hen Liu; Paul-Yang Lin; Wen-Cheng Chen
Journal:  J Mol Med (Berl)       Date:  2008-12-16       Impact factor: 4.599

10.  Ubiquitin/SUMO modification regulates VHL protein stability and nucleocytoplasmic localization.

Authors:  Qiliang Cai; Erle S Robertson
Journal:  PLoS One       Date:  2010-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.